Magdalena Zemelka-Wiacek

Nov 29, 2024 | mdpi.com | Magdalena Zemelka-Wiacek

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Sep 26, 2024 | onlinelibrary.wiley.com | Marek Jutel |Magdalena Zemelka-Wiacek |Oliver Pfaar

AIT allergen immunotherapy EMA European Medicines Agency MS mass spectrometry Ph.Eur. European Pharmacopoeia The standardization of allergen products is very challenging due to significant differences in quality and quantity, aggravated by the absence of uniform standards in Europe. This poses a difficulty for physicians in selecting an allergen product that meets specific patient's needs.

Nov 20, 2023 | onlinelibrary.wiley.com | Magdalena Zemelka-Wiacek |Ioana Agache |Cezmi A. Akdis |Mübeccel Akdis

1 INTRODUCTION Allergen immunotherapy (AIT) was initially reported at the beginning of the 20th century and performed in clinical routine for more than 110 years.1 A high level of evidence for its efficacy and safety has been elaborated throughout the recent decades for various forms of application, sublingual (SLIT) and subcutaneous (SCIT), as well as oral immunotherapy (OIT), the latter being used in managing food allergies, especially peanut, cow's milk and hen's egg allergy (Table 1).2-7...